Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$8.85 +0.3%	$8.08	$3.76 ▼ $46.80	$54.44M	2.77	170,096 shs	30,745 shs
BTAI BioXcel Therapeutics	$5.04 +2.4%	$2.49	$1.17 ▼ $13.36	$30.54M	0.05	5.10 million shs	5.35 million shs
JSPR Jasper Therapeutics	$2.85	$4.04	$2.27 ▼ $26.05	$42.81M	2.7	508,589 shs	119,520 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	+0.57%	+18.71%	-3.71%	+56.66%	-38.11%
BTAI BioXcel Therapeutics	-13.23%	-27.65%	+157.59%	+253.96%	-56.69%
JSPR Jasper Therapeutics	-2.73%	0.00%	-14.41%	-40.87%	-84.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALGS Aligos Therapeutics	4.4194 of 5 stars	3.5	4.0	4.8	2.4	1.7	0.6
BTAI BioXcel Therapeutics	4.5292 of 5 stars	3.4	5.0	4.5	2.9	1.7	0.6
JSPR Jasper Therapeutics	2.9182 of 5 stars	4.3	4.0	0.0	0.8	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	3.00	Buy	$50.00	464.97% Upside
BTAI BioXcel Therapeutics	2.80	Moderate Buy	$39.75	688.69% Upside
JSPR Jasper Therapeutics	2.60	Moderate Buy	$28.75	908.77% Upside

Current Analyst Ratings Breakdown

Latest BTAI, ALGS, and JSPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
8/15/2025	BTAI BioXcel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00
8/15/2025	JSPR Jasper Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$29.00 ➝ $25.00
7/8/2025	JSPR Jasper Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$5.00
7/8/2025	JSPR Jasper Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$70.00 ➝ $12.00
7/8/2025	JSPR Jasper Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$50.00 ➝ $20.00
7/8/2025	JSPR Jasper Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/7/2025	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
7/7/2025	JSPR Jasper Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$3.17M	17.15	N/A	N/A	$16.56 per share	0.53
BTAI BioXcel Therapeutics	$2.27M	13.45	N/A	N/A	($17.78) per share	-0.28
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$1.56 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$131.21M	-$19.79	N/A	N/A	N/A	-2,337.24%	-22.41%	-12.09%	11/5/2025 (Estimated)
BTAI BioXcel Therapeutics	-$59.60M	-$12.64	N/A	N/A	N/A	-5,869.82%	N/A	-134.45%	N/A
JSPR Jasper Therapeutics	-$71.27M	-$6.01	N/A	N/A	N/A	N/A	-172.28%	-128.34%	11/6/2025 (Estimated)

Latest BTAI, ALGS, and JSPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	JSPR Jasper Therapeutics	-$1.20	-$1.74	-$0.54	-$1.74	N/A	N/A
8/12/2025	Q2 2025	BTAI BioXcel Therapeutics	-$2.30	-$2.45	-$0.15	-$2.45	$0.21 million	$0.12 million
8/6/2025	Q2 2025	ALGS Aligos Therapeutics	-$2.35	-$1.53	+$0.82	-$1.53	$0.43 million	$0.97 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
BTAI BioXcel Therapeutics	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	6.31	6.31
BTAI BioXcel Therapeutics	N/A	0.76	0.74
JSPR Jasper Therapeutics	N/A	2.10	2.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
BTAI BioXcel Therapeutics	30.68%
JSPR Jasper Therapeutics	79.85%

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	4.80%
BTAI BioXcel Therapeutics	21.20%
JSPR Jasper Therapeutics	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	90	6.15 million	5.86 million	No Data
BTAI BioXcel Therapeutics	90	6.06 million	4.77 million	Optionable
JSPR Jasper Therapeutics	20	15.02 million	14.33 million	Optionable

BTAI, ALGS, and JSPR Headlines

Recent News About These Companies

HC Wainwright Issues Pessimistic Outlook for JSPR Earnings

August 19 at 2:45 AM | americanbankingnews.com

William Blair Issues Pessimistic Outlook for JSPR Earnings

August 19 at 2:45 AM | americanbankingnews.com

UBS Group Cuts Jasper Therapeutics (NASDAQ:JSPR) Price Target to $25.00

August 18 at 3:37 AM | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

August 17 at 11:56 AM | globenewswire.com

Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $29.75

August 17 at 2:01 AM | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

August 16, 2025 | prnewswire.com

BTIG Keeps Their Buy Rating on Jasper Therapeutics (JSPR)

August 15, 2025 | theglobeandmail.com

Jasper Therapeutics price target lowered to $25 from $29 at UBS

August 15, 2025 | msn.com

Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)

August 14, 2025 | msn.com

Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 14, 2025 | finanznachrichten.de

Jasper Reports Wider Loss in Fiscal Q2

August 14, 2025 | aol.comA

Jasper Therapeutics Reports Promising Q2 2025 Results

August 14, 2025 | msn.com

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

August 13, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

August 11, 2025 | prnewswire.com

Jasper Therapeutics (JSPR) Expected to Announce Quarterly Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

August 9, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

August 6, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

August 1, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

July 31, 2025 | prnewswire.com

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of "Moderate Buy" from Analysts

July 20, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI, ALGS, and JSPR Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$8.85 +0.03 (+0.34%)

Closing price 04:00 PM Eastern

Extended Trading

$8.88 +0.03 (+0.28%)

As of 05:15 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

BioXcel Therapeutics NASDAQ:BTAI

$5.04 +0.12 (+2.44%)

Closing price 04:00 PM Eastern

Extended Trading

$5.03 -0.01 (-0.20%)

As of 05:44 PM Eastern

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Jasper Therapeutics NASDAQ:JSPR

$2.85 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.86 +0.02 (+0.53%)

As of 04:10 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time